What Everygene does

Everygene, PBC is a US-based Public Benefit Corporation that sells direct-to-consumer genetic health screening to health-conscious adults. Its sole commercial product, the Everygene Health Screen, is an at-home cheek-swab test that evaluates an 84-gene panel focused on medically actionable conditions. Customers receive results without a physician order, and positive findings include free genetic counseling.

The company outsources clinical laboratory processing to Mass General Brigham, an institutional partnership that supplies clinical-grade credibility typically unavailable to a 2024-founded DTC entrant. Results are delivered to consumers and include downloadable VCF files, giving customers portability of their raw genetic data. The product is positioned as a one-time purchase rather than a subscription, with pricing currently set at $199 per test after a reduction from the original $399 launch price.

Everygene operates a pure-play direct-to-consumer e-commerce model, with no disclosed enterprise, employer, payer, or health-system channels and no prescription requirement at point of sale. The PBC corporate structure aligns the entity's charter with public-benefit objectives around broader access to genetic information. The company is at an early operating stage: no funding rounds, management team, headcount, or revenue figures have been disclosed in the available material.

Name

Everygene

Legal name

Everygene, PBC

Website

https://everygene.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Everygene is a US-based Public Benefit Corporation offering direct-to-consumer genetic health screening via an at-home cheek-swab test covering 84 medically actionable genes, with lab processing through Mass General Brigham and a one-time $199 price point.

Ownership category

akta.pro rank

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. Genetic Health Screen Kit Sales: One-time purchase of at-home genetic screening kit. Customers pay upfront for the test, with no subscription or recurring fees. Positive test results include free 30-minute genetic counseling session.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Everygene is a direct-to-consumer genetic health screening company that sells a one-time at-home cheek swab test analyzing 84 genes linked to serious, medically actionable hereditary conditions. The sample is processed through a hospital-grade laboratory partnership with Mass General Brigham, with results returned directly to the consumer without requiring a physician order.

Product overview

Everygene offers a single unified product: the Everygene Health Screen. This at-home genetic screening test analyzes 84 genes associated with treatable and preventable conditions, using a simple cheek swab methodology. Results are processed to hospital-grade standards in collaboration with Mass General Brigham. The product is priced at $199 (reduced from $399) and is designed as a one-time purchase with no subscription required, providing downloadable genome files (.vcf) and optional genetic counseling for positive results.

Differentiator

Problem solved

Functional benefit

Products and services

• Everygene Health Screen A one-time at-home genetic test sold directly to U.S. consumers that uses a cheek-swab sample to analyze 84 genes associated with serious, medically actionable hereditary conditions, with analysis performed by Mass General Brigham laboratories and results returned to the consumer without a prescription.

Quantifiable outcome

• 3% detection rate identifies carriers of genes linked to preventable/treatable conditions among ~10 million Americans

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Mass General BrighamcoreStrategic or Co-development PartnerMass General Brigham provides hospital-grade testing standards and clinical validation for Everygene's genetic health screen. Their lab processes samples and ensures results meet the same trusted standards used in major hospital systems. This partnership enables Everygene to offer clinical-quality genetic testing without requiring a prescription or hospital visit.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• MyHeritage: MyHeritage offers DTC DNA testing for ancestry and health. Directly competes in the consumer genetic testing category with similar e-commerce distribution and at-home kit delivery model.
• Color Health: Color Health provides clinical-grade genetic testing focused on preventive health, hereditary cancer, and pharmacogenomics. Comparable medically-actionable gene panel approach with both DTC and employer channels.
• 23andMe: 23andMe is the dominant DTC genetic testing company offering health, ancestry, and trait reports. Directly competes with Everygene on the consumer-facing genetic health screen category, though with broader ancestry and wellness features.
• Nebula Genomics: Nebula Genomics offers whole genome sequencing directly to consumers with privacy-focused positioning. Comparable DTC whole-genome approach and downloadable data files (similar VCF delivery).
• Ancestry: Ancestry operates one of the largest DTC DNA testing services, primarily ancestry-focused but expanding into health. Comparable DTC distribution model and consumer brand awareness in the genetic testing space.
• Veritas Genetics: Veritas Genetics provides whole genome sequencing with health interpretation, including medically actionable findings. Comparable DTC positioning with clinical-grade results and downloadable genome data.

Emerging players

• Helix: Helix operates a DNA testing platform serving both consumers and partners through an app-based marketplace. Comparable DTC distribution with broader ecosystem play and clinical lab infrastructure.

Broad incumbents

• Invitae: Invitae is a major clinical genetics company offering comprehensive genetic testing across multiple specialties. Provides overlapping test capabilities but primarily serves clinicians rather than DTC consumers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/everygene

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Everygene